Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mercaptamine ophthalmic - Leadiant Biosciences

Next Previous
Drug Profile

Mercaptamine ophthalmic - Leadiant Biosciences

Alternative Names: Cystaran; Cysteamine; Cysteamine HCl; Cysteamine hydrochloride; Cysteamine ophthalmic solution; Dropcys; LB-201 - Leadiant Biosciences; LB-202; LB201

Latest Information Update: 27 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sigma-Tau Pharmaceuticals
  • Developer Leadiant Biosciences; Lucane Pharma
  • Class Anti-inflammatories; Antibacterials; Antidotes; Hepatoprotectants; Mercaptoethylamines; Mucolytics; Small molecules
  • Mechanism of Action Glutathione synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystinosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystinosis

Most Recent Events

  • 31 May 2024 Preregistration for Cystinosis in Canada (Ophthalmic) prior to May 2024
  • 31 May 2024 Health Canada accepts the marketing authorization application of Mercaptamine ophthalmic for Cystinosis
  • 29 Jul 2022 Preclinical trials in Cystinosis (New delivery system) in USA (Ophthalmic) (Leadiant Biosciences Pipeline, July 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top